Drugs and FDA Approval - Clinical Research Informer

FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism

Pharmaceutical Technology

AUGUST 13, 2024

Ascendis Pharma has obtained US Food and Drug Administration (FDA) approval for its YORVIPATH to treat hypoparathyroidism in adults.

FDA Approval

FDA Approval Drugs

US FDA approves Bausch + Lomb and Novaliq’s DED treatment Miebo

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has granted approval to Bausch + Lomb and Novaliq’s Miebo (perfluorohexyloctane ophthalmic solution) to treat the signs and symptoms of dry eye disease (DED). It is the first and only prescription eye drop to receive FDA approval to treat DED that targets tear evaporation directly.

FDA Approval

FDA Approval Trials Marketing Development

In first, FDA approves KRAS-blocking cancer drug from Amgen

Bio Pharma Dive

MAY 28, 2021

Lumakras is the first drug proven effective. For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers.

FDA Approval

FDA Approval Drugs Gene Scientist

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

FDA Approves New Alzheimer’s Drug Designed to Slow Cognitive Decline

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 10, 2023

The US Food and Drug Administration (FDA) on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer’s disease.

FDA Approval

FDA Approval Drugs Clinical Trials Clinical Trials

FDA approves first-of-its-kind lupus drug

Bio Pharma Dive

JANUARY 25, 2021

Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year.

FDA Approval

FDA Approval Drugs Development

Lilly wins FDA approval of new kind of diabetes drug

Bio Pharma Dive

MAY 13, 2022

Tirzepatide, now branded as Mounjaro, helped improve blood sugar control in testing and has been shown to have powerful weight loss effects as well, making it one of the most closely watched drugs in Lilly's pipeline.

FDA Approval

FDA Approval Drugs Branding

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

Bio Pharma Dive

JANUARY 30, 2025

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

FDA Approval

FDA Approval Doctors Doctor Drugs

US FDA approves Shorla’s oncology drug for T-cell leukaemia

Pharmaceutical Technology

MARCH 8, 2023

The US Food and Drug Administration (FDA) has granted approval for Shorla Oncology’s Nelarabine Injection, an oncology drug, to treat T-cell leukaemia, an aggressive blood and bone marrow cancer that progresses quickly. The company develops innovative oncology drugs with a focus on paediatric and orphan cancers.

FDA Approval

FDA Approval Drugs Production Development

Madrigal wins FDA approval of first drug for MASH

Bio Pharma Dive

MARCH 14, 2024

But its sales potential is unclear, and competition could emerge from popular weight loss drugs. Rezdiffra’s clearance is a turning point in the fight against the liver disease.

FDA Approval

FDA Approval Drugs Sales

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

Bio Pharma Dive

JANUARY 6, 2023

The agency’s approval comes months after a large clinical trial showed the drug, called Leqembi, could slow the disease’s progression. Yet experts have raised concerns about its safety.

FDA Approval

FDA Approval Clinical Trials Clinical Trials Drugs

Gilead's Veklury becomes first FDA-approved drug for COVID-19

Bio Pharma Dive

OCTOBER 22, 2020

regulator granted a full approval after allowing emergency use earlier this year. New results from an WHO study, however, raise questions about the drug's ultimate effectiveness.

FDA Approval

FDA Approval Drugs Regulation

AstraZeneca wins first FDA approval for systemic lupus drug in a decade

Bio Pharma Dive

AUGUST 2, 2021

The regulator cleared Saphnelo despite mixed clinical trial data, giving patients another option after the recent OK for a drug aimed at the autoimmune disease's severe side effects.

FDA Approval

FDA Approval Clinical Trials Clinical Trials Drugs

FDA approves first microbiota-based treatment

Bio Pharma Dive

DECEMBER 1, 2022

The regulatory OK, a milestone for microbiome-based drug research, is for a medicine from Ferring Pharma that treats a recurrent type of gut infection.

FDA Approval

FDA Approval Medicine Drugs Research

FDA approves cancer drugs from Lilly, Menarini

Bio Pharma Dive

JANUARY 30, 2023

The agency’s clearance of Jaypirca gives Lilly another win from its Loxo buyout, while Menarini Group’s bet on Radius Health’s oral SERD has now paid off with Orserdu’s OK.

FDA Approval

FDA Approval Drugs

Seagen, Astellas win expanded FDA approval for bladder cancer drug

Bio Pharma Dive

APRIL 4, 2023

The first-line approval of Padcev together with Keytruda is viewed as important to expanding the drug’s market, and comes weeks after Pfizer agreed to buy Seagen for $43 billion.

FDA Approval

FDA Approval Drugs Marketing

FDA approves Seres’ microbiota drug for recurrent gut infection

Bio Pharma Dive

APRIL 26, 2023

The drug is the first microbiota-based pill to win U.S. Like a rival therapy approved in December, it’s for difficult-to-treat C. diff infections.

FDA Approval

FDA Approval Drugs

First-of-its-kind Type 1 diabetes drug wins FDA approval

Bio Pharma Dive

NOVEMBER 18, 2022

To be sold as Tzield, the drug will cost $193,900 for a typical full regimen. Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes.

FDA Approval

FDA Approval Drugs

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Bio Pharma Dive

DECEMBER 22, 2021

But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness. Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations.

Sales

Sales FDA Approval Doctors Doctor

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

JANUARY 7, 2025

In a major leap forward for trauma care, Humacyte has received full approval from the US Food and Drug Administration (FDA) for Symvess, a first-of-its-kind bioengineered human tissue designed to repair extremity arterial injuries. Symvess does carry risks, including thrombosis, graft rupture and infection.

FDA Approval

FDA Approval Engineer Clinical Trials Clinical Trials

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

Bio Pharma Dive

JANUARY 11, 2023

Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort.

FDA Approval

FDA Approval Drugs Sales Medicine

FDA approves Sanofi’s long-lasting hemophilia drug

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval

FDA Approval Drugs Protein Marketing

US FDA approves Reata Pharmaceuticals’ SKYCLARYS for Friedreich’s ataxia

Pharmaceutical Technology

MARCH 2, 2023

The US Food and Drug Administration (FDA) has approved Reata Pharmaceuticals ’ oral, once-daily medication SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia patients. SKYCLARYS is the first approved treatment in Friedrich’s Ataxia and marks a milestone for drug development in this complex disease.

FDA Approval

FDA Approval Trials Genetics Drugs

Xolair amplifies reach after FDA approval for treating food allergies

Pharmaceutical Technology

FEBRUARY 20, 2024

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Allergies

Allergies FDA Approval Drugs

Seagen, Genmab win speedy FDA approval for cervical cancer drug

Bio Pharma Dive

SEPTEMBER 21, 2021

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

FDA Approval

FDA Approval Drugs Antibody Medicine

FDA approves Regeneron drug for rare, genetic form of high cholesterol

Bio Pharma Dive

FEBRUARY 12, 2021

The biotech set an average annual price of $450,000 for the first-of-its-kind drug, which treats a condition that affects about 1,300 people in the U.S.

FDA Approval

FDA Approval Genetics Drugs

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Bio Pharma Dive

MARCH 7, 2023

As many as a third of FDA-approved drugs target GPCRs in some fashion, with uses ranging from treating cancer to pain. But biotech startups say there is still room to develop more.

Protein

Protein FDA Approval Drugs Development

Kebilidi FDA-Approved as First Brain-Delivered Gene Therapy for AADC Deficiency

XTalks

NOVEMBER 14, 2024

PTC Therapeutics has gained US Food and Drug Administration (FDA) approval for its new gene therapy, Kebilidi (eladocagene exuparvovec), for treating aromatic L-amino acid decarboxylase (AADC) deficiency.

Gene Therapy

Gene Therapy FDA Approval Gene Clinical Trials

FDA approves new ALS medicine in precedent-setting decision

Bio Pharma Dive

APRIL 25, 2023

Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.

FDA Approval

FDA Approval Medicine Protein Marketing

FDA approves oral version of Mitsubishi's ALS drug

Bio Pharma Dive

MAY 13, 2022

Called Radicava ORS, this version is taken by mouth rather than via an hourlong infusion, which may help improve the drug's convenience and use.

FDA Approval

FDA Approval Drugs

Takeda wins FDA approval for targeted lung cancer drug

Bio Pharma Dive

SEPTEMBER 16, 2021

Unlike J&J's drug, however, Takeda's is given orally. Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene.

FDA Approval

FDA Approval Drugs Gene Marketing

Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug

Bio Pharma Dive

SEPTEMBER 11, 2023

The HER3-targeting treatment could become the next antibody-drug conjugate to emerge from Daiichi Sankyo’s laboratories, after the AstraZeneca-partnered Enhertu.

FDA Approval

FDA Approval Drugs Antibody

Roche wins FDA approval for rival to Regeneron's lucrative eye drug

Bio Pharma Dive

JANUARY 31, 2022

The drug, which will be sold as Vabysmo, is the first of several emerging competitive threats to Regeneron's top-selling Eylea, along with biosimilars and long-acting implants.

FDA Approval

FDA Approval Drugs

US FDA approves Ferring’s Rebyota for Clostridioides difficile infection

Pharmaceutical Technology

DECEMBER 1, 2022

The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above. A live biotherapeutic, Rebyota is intended for usage following the completion of antibiotic treatment.

FDA Approval

FDA Approval Trials Clinical Development Development

FDA approves Ascendis drug for rare endocrine condition

Bio Pharma Dive

AUGUST 12, 2024

The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.

FDA Approval

FDA Approval Drugs

In historic move, FDA approves a closely watched and controversial Alzheimer's drug

Bio Pharma Dive

JUNE 7, 2021

With the decision, the agency cleared the way for what many predict will become a lucrative and highly sought-after option — though fierce debate continues over whether the medicine, Biogen's aducanumab, actually benefits patients' daily lives.

FDA Approval

FDA Approval Medicine Drugs

5 FDA approval decisions to watch in the 1st quarter

Bio Pharma Dive

JANUARY 5, 2021

By March, the FDA expects to conclude reviews of key drugs for heart failure, Duchenne's and multiple myeloma, as well as decide on whether to clear Biogen's controversial Alzheimer's treatment.

FDA Approval

FDA Approval Drugs

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. In the trial, 1.9%

FDA Approval

FDA Approval Clinical Trials Clinical Trials Engineer

Sarepta wins FDA approval of another drug for rare muscular dystrophy

Bio Pharma Dive

FEBRUARY 25, 2021

Like other Sarepta drugs, it comes with a high price tag and its clinical benefits haven't been confirmed. Amondys 45 is now cleared for the estimated 8% of Duchenne patients eligible for treatment.

FDA Approval

FDA Approval Drugs

Apellis wins FDA approval of first drug for type of vision loss

Bio Pharma Dive

FEBRUARY 17, 2023

Apellis’ Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.

FDA Approval

FDA Approval Drugs Marketing

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Bio Pharma Dive

JANUARY 18, 2022

AbbVie's Rinvoq and Pfizer's Cibinqo are both JAK-inhibiting drugs that are taken orally, a convenience which could help them compete against injectable treatments like Sanofi and Regeneron's Dupixent.

FDA Approval

FDA Approval Drugs

FDA approves Lilly, Boehringer diabetes drug for heart failure

Bio Pharma Dive

AUGUST 19, 2021

The expanded clearance in heart failure with reduced ejection fraction is expected to boost sales of the drug, called Jardiance.

FDA Approval

FDA Approval Drugs Sales

Lilly drug Mounjaro succeeds in second weight loss study

Bio Pharma Dive

APRIL 27, 2023

Trial participants lost up to 15% of their body weight in a finding that should help the closely watched GLP-1 drug gain an FDA approval for obesity.

FDA Approval

FDA Approval Drugs Trials

Journey slips on FDA approval of rosacea therapy

pharmaphorum

NOVEMBER 5, 2024

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term (..)

FDA Approval

FDA Approval Regulation Drugs

Biohaven to seek FDA approval for second migraine drug after study success

Bio Pharma Dive

DECEMBER 6, 2021

The biotech's drug, called zavegepant, is delivered intranasally and could offer a similar convenience advantage as its first, the fast-selling Nurtec ODT.

FDA Approval

FDA Approval Drugs

FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism

US FDA approves Bausch + Lomb and Novaliq’s DED treatment Miebo

Webinars

Trending Sources

In first, FDA approves KRAS-blocking cancer drug from Amgen

Webinars

FDA Approves New Alzheimer’s Drug Designed to Slow Cognitive Decline

FDA approves first-of-its-kind lupus drug

Lilly wins FDA approval of new kind of diabetes drug

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

US FDA approves Shorla’s oncology drug for T-cell leukaemia

Madrigal wins FDA approval of first drug for MASH

FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision

Gilead's Veklury becomes first FDA-approved drug for COVID-19

AstraZeneca wins first FDA approval for systemic lupus drug in a decade

FDA approves first microbiota-based treatment

FDA approves cancer drugs from Lilly, Menarini

Seagen, Astellas win expanded FDA approval for bladder cancer drug

FDA approves Seres’ microbiota drug for recurrent gut infection

First-of-its-kind Type 1 diabetes drug wins FDA approval

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma

FDA approves Sanofi’s long-lasting hemophilia drug

US FDA approves Reata Pharmaceuticals’ SKYCLARYS for Friedreich’s ataxia

Xolair amplifies reach after FDA approval for treating food allergies

Seagen, Genmab win speedy FDA approval for cervical cancer drug

FDA approves Regeneron drug for rare, genetic form of high cholesterol

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Kebilidi FDA-Approved as First Brain-Delivered Gene Therapy for AADC Deficiency

FDA approves new ALS medicine in precedent-setting decision

FDA approves oral version of Mitsubishi's ALS drug

Takeda wins FDA approval for targeted lung cancer drug

Daiichi Sankyo, with new data, to seek FDA approval of lung cancer drug

Roche wins FDA approval for rival to Regeneron's lucrative eye drug

US FDA approves Ferring’s Rebyota for Clostridioides difficile infection

FDA approves Ascendis drug for rare endocrine condition

In historic move, FDA approves a closely watched and controversial Alzheimer's drug

5 FDA approval decisions to watch in the 1st quarter

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

Sarepta wins FDA approval of another drug for rare muscular dystrophy

Apellis wins FDA approval of first drug for type of vision loss

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

FDA approves Lilly, Boehringer diabetes drug for heart failure

Lilly drug Mounjaro succeeds in second weight loss study

Journey slips on FDA approval of rosacea therapy

Biohaven to seek FDA approval for second migraine drug after study success

Stay Connected